⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1268642 | 1.00 | — | — | |
| SCHEMBL7296532 | 0.81 | — | — | |
| SCHEMBL7296063 | 0.81 | — | — | |
| SCHEMBL7296058 | 0.81 | — | — | |
| SCHEMBL7296527 | 0.81 | — | — | |
| SCHEMBL7293670 | 0.79 | TSHR (0.48) | — | |
| SCHEMBL7290213 | 0.79 | TSHR (0.48) | — | |
| SCHEMBL7290210 | 0.79 | TSHR (0.48) | — | |
| SCHEMBL7293877 | 0.79 | TSHR (0.48) | — | |
| SCHEMBL7293873 | 0.79 | TSHR (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2266978-B1 | Novel physiologically active substances | EISAI R&D MAN CO LTD (JP) | 2015-05-20 | — | — | EP | disclosed |
| US-7932083-B2 | Ferrodoxins; hydroxylases; self-replicating plasmid | MERCIAN CORPORATION (JP) | 2011-04-26 | — | — | US | disclosed |
| US-7893068-B2 | Macrolide compounds comprising 18,19-epoxytricosa-8,12,14-trien-11-olide derivatives; angiogenesis inhibitors; anticarcinogenic, antimetastasis, antiinflammatory, and antitumor agents; antihypoxic agents; endothelial growth factor suppressors; retinal neovascularization, diabetic retinopathy | MERCIAN CORPORATION (JP) | 2011-02-22 | — | — | US | disclosed |
| EP-2266978-A1 | Novel physiologically active substances | MERCIAN CORPORATION (JP) | 2010-12-29 | — | — | EP | disclosed |
| US-20100086931-A1 | METHOD FOR ASSAYING ACTION OF ANTITUMOR AGENT USING DECREASE IN GENE EXPRESSION LEVEL AS INDEX | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-08 | — | — | US | disclosed |
| US-20100021918-A1 | METHOD FOR ASSAYING ACTION OF ANTITUMOR AGENT USING SPLICING DEFECTS AS INDEX | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-01-28 | — | — | US | disclosed |
| EP-2136209-A1 | METHOD FOR EXAMINATION OF ACTION OF ANTI-CANCER AGENT UTILIZING SPLICING DEFECT AS MEASURE | Eisai R&D Management Co., Ltd. (JP) | 2009-12-23 | — | — | EP | disclosed |
| EP-2131193-A1 | METHOD FOR EXAMINATION OF ACTIVITY OF ANTI-CANCER AGENT EMPLOYING REDUCTION IN EXPRESSION LEVEL OF GENE AS MEASURE | Eisai R&D Management Co., Ltd. (JP) | 2009-12-09 | — | — | EP | disclosed |
| US-7619100-B2 | Physiologically active substances | MERCIAN CORPORATION (JP) | 2009-11-17 | — | — | US | disclosed |
| US-7550503-B2 | Physiologically active substances | EISAI R& D MANAGEMENT CO., LTD. (JP) | 2009-06-23 | — | — | US | disclosed |
| US-20080275059-A1 | NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCES | KOTAKE YOSHIHIKO | 2008-11-06 | — | — | US | disclosed |
| US-20080255146-A1 | NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCES | MICROBIOPHARM JAPAN CO., LTD. (JP) | 2008-10-16 | — | — | US | disclosed |
| US-20080070286-A1 | Dna Participating in Hydroxylation of Macrolide Compound | SANLI HOLDINGS CO., LTD. (JP) | 2008-03-20 | — | — | US | disclosed |
| US-20060241171-A1 | Novel physiologically active substances | MICROBIOPHARM JAPAN CO., LTD. (JP) | 2006-10-26 | — | — | US | disclosed |
| EP-1705247-A1 | DNA PARTICIPATING IN HYDROXYLATION OF MACROLIDE COMPOUND | MERCIAN CORPORATION (JP) | 2006-09-27 | — | — | EP | disclosed |
| US-20060009439-A1 | Novel physiologically active substances | MERCIAN CORPORATION (JP) | 2006-01-12 | — | — | US | disclosed |
| EP-1508570-A1 | NOVEL PHYSIOLGICALLY ACTIVE SUBSTANCES | MERCIAN CORPORATION (JP) | 2005-02-23 | — | — | EP | disclosed |